These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 27485727)

  • 21. Comparison of mailed invitation strategies to improve fecal occult blood test participation in men: protocol for a randomized controlled trial.
    Duncan A; Zajac I; Flight I; Stewart BJ; Wilson C; Turnbull D
    Trials; 2013 Jul; 14():239. PubMed ID: 23902589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An advance notification letter increases participation in colorectal cancer screening.
    Cole SR; Smith A; Wilson C; Turnbull D; Esterman A; Young GP
    J Med Screen; 2007; 14(2):73-5. PubMed ID: 17626705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advance notification letters increase adherence in colorectal cancer screening: a population-based randomized trial.
    van Roon AH; Hol L; Wilschut JA; Reijerink JC; van Vuuren AJ; van Ballegooijen M; Habbema JD; van Leerdam ME; Kuipers EJ
    Prev Med; 2011 Jun; 52(6):448-51. PubMed ID: 21457725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SMARTERscreen protocol: a three-arm cluster randomised controlled trial of patient SMS messaging in general practice to increase participation in the Australian National Bowel Cancer Screening Program.
    McIntosh JG; Emery JD; Wood A; Chondros P; Goodwin BC; Trevena J; Wilson C; Chang S; Hocking J; Campbell T; Macrae F; Milley K; Lew JB; Nightingale C; Dixon I; Castelli M; Lee N; Innes L; Jolley T; Fletcher S; Buchanan L; Doncovio S; Broun K; Austin G; Jiang J; Jenkins MA
    Trials; 2023 Nov; 24(1):723. PubMed ID: 37957680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-notification and reminder SMS text messages with behaviourally informed invitation letters to improve uptake of NHS Health Checks: a factorial randomised controlled trial.
    Sallis A; Sherlock J; Bonus A; Saei A; Gold N; Vlaev I; Chadborn T
    BMC Public Health; 2019 Aug; 19(1):1162. PubMed ID: 31438908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying and prioritising gaps in colorectal cancer trials research in Australia.
    Dear RF; Barratt AL; Evans A; Simes J; Newsom J; Kent D; Crossing S; Holliday C; Segelov E; Hruby G; Tattersall MH
    Med J Aust; 2012 Nov; 197(9):507-11. PubMed ID: 23121587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The implementation and mechanisms of advance notification for cancer screening: A scoping review.
    Collins KE; Myers LS; Goodwin BC; Taglieri-Sclocchi A; Ireland MJ
    Psychooncology; 2024 Apr; 33(4):e6340. PubMed ID: 38588033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Theory-based modifications of an advanced notification letter improves screening for bowel cancer in men: A randomised controlled trial.
    Zajac IT; Duncan AC; Flight I; Wittert GA; Cole SR; Young GP; Wilson CJ; Turnbull DA
    Soc Sci Med; 2016 Sep; 165():1-9. PubMed ID: 27485727
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 30.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.